CIS43LS单克隆抗体预防疟疾的1期临床试验
该两阶段1期临床试验评估了长效抗疟单克隆抗体CIS43LS在从未患疟疾的健康成人中的安全性、药代动力学及抗恶性疟原虫感染效力。25名参与者接受5、20或40 mg/kg剂量,未发现安全性问题,血清浓度呈剂量依赖性升高,半衰期为56天。受控感染后,9名接受CIS43LS者均无疟原虫血症,而6名对照中5名出现疟原虫血症。
要点
- CIS43LS在健康成人中安全性良好,血清浓度呈剂量依赖性升高,半衰期56天。
- 受控感染后21天内,9名接受CIS43LS者均无疟原虫血症,6名对照中5名出现疟原虫血症。
- 接受40 mg/kg的2名参与者在约36周后受控感染时仍无疟原虫血症。
核心结论
- 长效单克隆抗体CIS43LS在从未患疟疾或接种疫苗的成人中可预防受控感染后的疟疾。
研究设计与样本
- 两阶段1期临床试验,评估CIS43LS的安全性、药代动力学及抗恶性疟原虫感染效力。
- 25名健康成人接受5、20或40 mg/kg剂量,其中4人接受第二剂20 mg/kg。
- 部分参与者接受受控人类疟疾感染,暴露于携带恶性疟原虫子孢子的蚊虫。
主要发现
- 25名参与者中未发现安全性问题。
- CIS43LS血清浓度呈剂量依赖性升高,半衰期为56天。
- 受控感染后21天内,9名接受CIS43LS者均无疟原虫血症,6名对照中5名出现疟原虫血症。
- 2名接受40 mg/kg者在约36周后受控感染时无疟原虫血症,当时血清浓度为46和57 μg/mL。
临床怎么用
- 提示长效单克隆抗体可能成为疟疾预防的补充干预手段,仍需进一步试验验证。
局限性
- 为1期小样本试验,受控感染条件与自然暴露不同,效力需在更大规模现场研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Additional interventions are needed to reduce the morbidity and mortality caused by malaria. METHODS: We conducted a two-part, phase 1 clinical trial to assess the safety and pharmacokinetics of CIS43LS, an antimalarial monoclonal antibody with an extended half-life, and its efficacy against infection with Plasmodium falciparum. Part A of the trial assessed the safety, initial side-effect profile, and pharmacokinetics of CIS43LS in healthy adults who had never had malaria. Participants received CIS43LS subcutaneously or intravenously at one of three escalating dose levels. A subgroup of participants from Part A continued to Part B, and some received a second CIS43LS infusion. Additional participants were enrolled in Part B and received CIS43LS intravenously. To assess the protective efficacy of CIS43LS, some participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying P. falciparum sporozoites 4 to 36 weeks after administration of CIS43LS. RESULTS: A total of 25 participants received CIS43LS at a dose of 5 mg per kilogram of body weight, 20 mg per kilogram, or 40 mg per kilogram, and 4 of the 25 participants received a second dose (20 mg per kilogram regardless of initial dose). No safety concerns were identified. We observed dose-dependent increases in CIS43LS serum concentrations, with a half-life of 56 days. None of the 9 participants who received CIS43LS, as compared with 5 of 6 control participants who did not receive CIS43LS, had parasitemia according to polymerase-chain-reaction testing through 21 days after controlled human malaria infection. Two participants who received 40 mg per kilogram of CIS43LS and underwent controlled human malaria infection approximately 36 weeks later had no parasitemia, with serum concentrations of CIS43LS of 46 and 57 μg per milliliter at the time of controlled human malaria infection. CONCLUSIONS: Among adults who had never had malaria infection or vaccination, administration of the long-acting monoclonal antibody CIS43LS prevented malaria after controlled infection. (Funded by the National Institute of Allergy and Infectious Diseases; VRC 612 ClinicalTrials.gov number, NCT04206332.).
引用
- Gaudinski MR, Berkowitz NM, Idris AH, et al. A Monoclonal Antibody for Malaria Prevention. N Engl J Med. 2021. PMID: 34379916. doi:10.1056/NEJMoa2034031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。